Isentress (Raltegravir)

Raltegravir blocks the HIV integrase enzyme, which is essential for inserting viral DNA into the host cell’s genome. By preventing this strand‑transfer step, the drug stops the virus from establishing a permanent infection in the cell, thereby inhibiting further replication of HIV.

The specific dose of Isentress is determined by the prescribing healthcare professional based on the patient’s age, weight, treatment history and the other antiretroviral agents being used. Only a qualified prescriber can set the appropriate dosing regimen.

Safety data for raltegravir in pregnancy are limited. The drug should only be used during pregnancy or while breastfeeding if the potential benefits outweigh the potential risks, and this decision must be made by the treating physician in consultation with the patient.

To order Isentress, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isentress (raltegravir) is a first‑generation integrase strand transfer inhibitor, offering a well‑characterised safety profile and rapid viral suppression. Compared with newer agents such as dolutegravir, raltegravir may require twice‑daily dosing and has a slightly lower barrier to resistance, but it remains an effective option for many treatment‑naïve and treatment‑experienced patients.

Isentress tablets should be stored at room temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Isentress is taken orally, usually as a tablet, with or without food. The exact timing relative to other antiretroviral medicines should follow the prescriber’s instructions, and patients should not crush or chew the tablets unless specifically directed to do so.

Serious risks include severe hypersensitivity reactions such as Stevens‑Johnson syndrome, significant liver enzyme elevations indicating hepatic injury, and rare metabolic disturbances like lactic acidosis. Patients should seek immediate medical attention if they develop rash, jaundice, unexplained fatigue, or abdominal pain.

Isentress should be avoided in individuals with known hypersensitivity to raltegravir or any other integrase strand transfer inhibitor. It is also contraindicated in patients who cannot safely take the required combination of antiretroviral agents as prescribed by their healthcare provider.